Profitability
Weight: 20%
F
5
- 5yr Avg ROIC -1.6%
- Operating Margin Trend -3.06 pp/yr
ANIK
Anika Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
22
- 5yr Avg ROE -17.4%
- 5yr Share-Count CAGR 0.2%
Growth Quality
Weight: 15%
F
22
- 5yr Revenue CAGR -2.9%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 15%
C-
46
- 5yr FCF Margin -0.9%
- 5yr FCF/NI Conversion 0.79x
Balance Sheet
Weight: 20%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 5.06
Stability
Weight: 15%
D+
43
- EPS Volatility (σ/μ) 0.45
- Negative-Revenue Years (5) 3/5
- Piotroski F-Score 5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 added; 1 trimmed.
- Holders
- 2
- Avg Δ position
- -8.2%
- New buys
- 0
- Full exits
- 0